Biotechnology · Geroscience
Gerostate Alpha
A Buck Institute spinout that screened tens of thousands of compounds in nematodes and pushed the winners into aging mice. One peer reviewed mouse result carries the company name. Its last SEC filing was in April 2022.
A worm compound that spared mouse bone
In 2011 a Buck Institute team led by Gordon Lithgow reported in Nature that a family of amyloid binding compounds extended the lifespan of the nematode Caenorhabditis elegans. One of them was 2-(2-hydroxyphenyl) benzoxazole, a small synthetic molecule designed from a laboratory dye. Worms have no skeleton.
A decade later, five Buck labs put that compound into the chow of middle aged mice and scanned their femurs by micro computed tomography until the animals died. Over a year of treatment, benzoxazole spared 31 percent of bone volume against untreated controls. Cortical thickness was 27 percent greater and bone cross sectional area 93 percent greater, all after correction for multiple testing.
“If you have a therapeutic that extends lifespan in a simple animal that has no bone whatsoever, you certainly wouldn’t predict that it would slow the rate of bone aging in a mammal,” Lithgow said when the Buck announced the result in January 2021.
The paper appeared in JBMR Plus that March. Almost every author lists a university or institute. One, Mark Lucanic, lists Gerostate Alpha. The conflict statement is short: “Simon Melov, Gordon J Lithgow, and Mark Lucanic are cofounders of Gerostate Alpha.” It is the only PubMed paper carrying the company as an affiliation.
The indication that does not exist
Aging is not an indication the US Food and Drug Administration recognizes. Drugs are approved to treat diseases, and there is no accepted endpoint for slowing the rate at which a body wears out. The best known workaround is the proposed Targeting Aging with Metformin trial, testing metformin in people aged 65 to 80 without diabetes against a composite of death or new major age related disease.
Lithgow co-authored a 2021 review that names the problem: private capital stays away because of “the focus of FDA’s congressional mandate on the diagnosis and treatment of diseases, combined with the fact that aging cannot be viewed as a ‘disease.’” Gerostate’s answer was to measure six organ systems at once and let a commercial indication emerge from whichever tissue responded.
The screening layer carries its own caution, documented by the founders. Lucanic co-authored a 2019 GeroScience paper from the NIA funded Caenorhabditis Intervention Testing Program, a three laboratory effort to find worm lifespan effects that reproduce. It reports “unexplained, but reproducible sources of variability for Caenorhabditis lifespan, particularly between experiments, even under a highly standardized and extensively documented series of protocols,” and that moving to automated scanners produced “radically contrasting results for certain compound interventions.”
Three scientists and a talk at the Buck
Melov was the third faculty hire when the Buck opened in 1999 and co-directs its mouse phenotyping core. Lithgow moved his aging lab from Manchester to the Buck in 2000 and is now Chief Academic Officer. Lucanic held a research assistant professorship there and specialised in high throughput screens.
What moved them, Melov told Longevity.Technology, was a 2018 visit from Y Combinator’s Sam Altman. “We pitched it to Y Combinator, they really liked us and gave us a million dollars to start the company. It was certainly the fastest million we ever made in our careers!” The company joined the Summer 2018 batch. Y Combinator’s published deal for that period was $120,000 for 7 percent.
Edward O. Lanphier II, founder and former chief executive of Sangamo Therapeutics, joined as executive chair and signed the 2022 annual report as a director.
Taking it to the crowd
By early 2021 the company said it had screened about 60,000 compounds and validated more than 30 hits, the best extending Caenorhabditis lifespan by roughly 40 percent. It had $2.1 million of seed money at a $15 million cap and needed more for mouse work. In April 2021 it opened a Regulation Crowdfunding campaign on Wefunder, days after the SEC raised the annual crowdfunding ceiling to $5 million.
The first offering closed that August. The Form C-U progress update gives one sentence: “The final number is $270,866.00 in investments.” A second offering opened in October at a $20 million cap. Then the filings stop.
What is proven, and what is still claimed
| Evidence | What the record shows | Source type |
|---|---|---|
| Mouse bone data | JBMR Plus, March 2021. 677 mice entered at 18 months from the NIA colony, 751 micro CT scans. Benzoxazole spared 31% of bone volume over a year; cortical thickness 27% greater, cross sectional area 93% greater, q below 0.05 for all three. | Public record |
| Mouse survival, same study | “In sex-adjusted analyses, no intervention was associated with survival.” Benzoxazole showed a non-significant hazard ratio of 0.83. Clioquinol raised mortality risk in males, hazard ratio 1.50. The NIA Interventions Testing Program had separately found benzoxazole did not extend mean lifespan in mice. | Public record |
| Screening output | About 60,000 compounds screened, more than 30 validated hits, best hits near 40% lifespan extension in Caenorhabditis, and a stated 20% platform success rate. None published. | Company-stated |
| Patents | A Google Patents search on September 23, 2026 found no patent or application assigned to Gerostate Alpha. Every founder patent in this area, including Use of thioflavin-like compounds to increase life span and/or health span, is assigned to the Buck Institute. | Public record |
| Clinical trials | A ClinicalTrials.gov search on September 23, 2026 returned zero studies. In January 2021 Melov described a two year path to Phase 1. | Not found |
| Federal grants to the company | NIH RePORTER returns zero awards. NIA money in this area went to the Buck Institute and to Lithgow as an academic investigator. | Not found |
| Size of the YC investment | Melov said YC gave the company a million dollars, and a longevity newsletter repeated a “notable $1M check from Y Combinator.” YC’s deal page, archived August 2018, states: “we’ll invest $120k in return for 7% of the company.” The $150,000 deal began with the Winter 2019 batch. | Differs from the record |
| Operating status | The Y Combinator directory lists the company as Inactive, team size 6. The last SEC filing is the annual report of April 28, 2022, with no Form C-TR terminating the reporting duty. On September 23, 2026 gerostatealpha.com served an unrelated gambling page. | Public record |
Read plainly: the science is real, published and checkable, and the bone effect in old mice was large enough that the authors compared it with bisphosphonates. What the record does not show is a company that turned it into an asset of its own. The compound came from Buck work, the patent sits with Buck, the worm result did not carry through as a mouse survival benefit, no trial was registered, and the filings stop in spring 2022.
What to watch
- Any new filing under CIK 0001858392. A Regulation Crowdfunding issuer owes an annual report until it files a Form C-TR; neither has appeared since April 2022.
- A follow up paper on benzoxazole in bone. The 2021 authors said the mechanism was still under study.
- Whether any screening hit surfaces in a Buck patent filing or another company.
- What happens to aging as a regulatory category. Nothing built on lifespan as a phenotype reaches patients until an agency accepts an endpoint.
In their words
“Our phenotype is lifespan. We’re looking for the magnitude of the increase in lifespan, and then we look to see what phenotypes associated with that lifespan extension are reduced in aging mice.”
Simon Melov, co-founder and CEO, Longevity.Technology, January 2021 · Interview
“We believe that these pillars of aging are just one of many, and we think that the major modulators of aging remain to be discovered.”
Simon Melov, Longevity.Technology, January 2021 · Interview
“Our initial strategy was to screen small molecule libraries, so we did that on around 60,000 compounds, and we identified over 30 hits that have been validated”
Mark Lucanic, co-founder and CTO, Longevity.Technology, January 2021 · Interview
“We have developed this machine which can produce candidates, and we want to crank that handle.”
Simon Melov, Longevity.Technology, July 2021 · Interview
“This approach was a bit of a mystery to us and we viewed it as a test campaign for crowdfunding the development of interventions for aging,”
Simon Melov, on the Wefunder round, Longevity.Technology, July 2021 · Interview
“A 31% reduction in bone loss late in life would be considered substantial if this was recapitulated in the aging human skeleton.”
Evans and colleagues, JBMR Plus, March 2021 · Peer reviewed
Related companies
Sources
- Public recordForms C, C-U and C-AR, CIK 0001858392
- Public recordLongitudinal Functional Study of Murine Aging
- Public recordFrom discoveries in ageing research to therapeutics for healthy ageing
- Public recordMoving geroscience from the bench to clinical care and health policy
- Public recordAutomated lifespan determination across Caenorhabditis strains and species
- Public recordAlpha-Ketoglutarate extends lifespan and compresses morbidity in aging mice
- Public recordPatent searches for the company and each founder
- Public recordStudy and award searches returning zero results
- Public recordThe Y Combinator Deal, archived
- IndependentThe major modulators of aging remain to be discovered
- IndependentGerostate Alpha: Our phenotype is lifespan
- IndependentGerostate Alpha opens crowdfunded capital raise
- IndependentGerostate passes crowdfunding goal for antiaging drug platform
- IndependentLongevity Marketcap Telemetry #027
- IndependentGerostate Alpha on Wefunder 2021
- CompanyA compound that slows bone loss, and a resource for developing treatments to slow aging
- CompanyGerostate Alpha website team page, archived
- CompanyCompany page, batch, team size and status
- Public recordgerostatealpha.com as served
Profile researched and written by Healthcare Discovery. Last updated September 29, 2026.
